This week’s edition of The Targeted Pulse spotlights 5 key developments shaping the landscape of targeted oncology.

Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...

Amcor's investment will enhance its capabilities for producing post-consumer recycled (PCR) packaging, offering customers flexible PCR content options up to 100% to meet sustainability goals and ...

In joint research with the University of Tokyo (UTokyo), the National Institute of Advanced Industrial Science and Technology ...

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

The authors provide solid evidence of its utility by benchmarking multiple demultiplexing methods and proposing a new variant consistency metric. While the tool is valuable for guiding method ...

The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.